🚀 VC round data is live in beta, check it out!
NervGen Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for NervGen Pharma and similar public comparables like Cybin, Rezolute, Clinuvel Pharmaceuticals, Zentalis Pharma and more.
NervGen Pharma Overview
About NervGen Pharma
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
Founded
2017
HQ
Employees
18
Website
Sectors
Financials (LTM)
EV
$313M
NervGen Pharma Financials
NervGen Pharma reported last 12-month revenue of — and negative EBITDA of ($21M).
In the same LTM period, NervGen Pharma generated ($21M) in EBITDA losses and had net loss of ($29M).
Revenue (LTM)
NervGen Pharma P&L
In the most recent fiscal year, NervGen Pharma reported revenue of — and EBITDA of ($18M).
NervGen Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($21M) | XXX | ($18M) | XXX | XXX | XXX |
| Net Profit | ($29M) | XXX | ($32M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
NervGen Pharma Stock Performance
NervGen Pharma has current market cap of $329M, and enterprise value of $313M.
Market Cap Evolution
NervGen Pharma's stock price is $4.07.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $313M | $329M | -2.2% | XXX | XXX | XXX | $-0.39 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNervGen Pharma Valuation Multiples
NervGen Pharma trades at (15.2x) EV/EBITDA.
NervGen Pharma Financial Valuation Multiples
As of April 18, 2026, NervGen Pharma has market cap of $329M and EV of $313M.
Equity research analysts estimate NervGen Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NervGen Pharma has a P/E ratio of (11.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $329M | XXX | $329M | XXX | XXX | XXX |
| EV (current) | $313M | XXX | $313M | XXX | XXX | XXX |
| EV/EBITDA | (15.2x) | XXX | (17.5x) | XXX | XXX | XXX |
| EV/EBIT | (15.6x) | XXX | (17.4x) | XXX | XXX | XXX |
| P/E | (11.4x) | XXX | (10.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (22.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified NervGen Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
NervGen Pharma Margins & Growth Rates
NervGen Pharma's revenue in the last fiscal year grew by —.
NervGen Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.
NervGen Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 31% | XXX | 50% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
NervGen Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| NervGen Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Cybin | XXX | XXX | XXX | XXX | XXX | XXX |
| Rezolute | XXX | XXX | XXX | XXX | XXX | XXX |
| Clinuvel Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Zentalis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Avalo Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NervGen Pharma M&A Activity
NervGen Pharma acquired XXX companies to date.
Last acquisition by NervGen Pharma was on XXXXXXXX, XXXXX. NervGen Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by NervGen Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNervGen Pharma Investment Activity
NervGen Pharma invested in XXX companies to date.
NervGen Pharma made its latest investment on XXXXXXXX, XXXXX. NervGen Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by NervGen Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout NervGen Pharma
| When was NervGen Pharma founded? | NervGen Pharma was founded in 2017. |
| Where is NervGen Pharma headquartered? | NervGen Pharma is headquartered in Canada. |
| How many employees does NervGen Pharma have? | As of today, NervGen Pharma has over 18 employees. |
| Is NervGen Pharma publicly listed? | Yes, NervGen Pharma is a public company listed on Nasdaq. |
| What is the stock symbol of NervGen Pharma? | NervGen Pharma trades under NGEN ticker. |
| When did NervGen Pharma go public? | NervGen Pharma went public in 2019. |
| Who are competitors of NervGen Pharma? | NervGen Pharma main competitors are Cybin, Rezolute, Clinuvel Pharmaceuticals, Zentalis Pharma. |
| What is the current market cap of NervGen Pharma? | NervGen Pharma's current market cap is $329M. |
| Is NervGen Pharma profitable? | No, NervGen Pharma is not profitable. |
| What is the current EBITDA of NervGen Pharma? | NervGen Pharma has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of NervGen Pharma? | Current EBITDA multiple of NervGen Pharma is (15.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.